Skip to main content
Premium Trial:

Request an Annual Quote

Expensive and Useless. Great.

A recent article in the American Journal of Human Genetics looks at the scientific basis behind commercial genomic profiles offered by seven companies. The researchers say there is "insufficient scientific evidence to conclude that genomic profiles are useful in measuring genetic risk for common diseases or in developing personalized diet and lifestyle recommendations for disease prevention." Blogger Yann Klimentidis agrees, saying that "basically, we're still years away from being able to tell people about their health risks or about how they should eat/behave based on their genetic information."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.